2017
PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE
Blondin N. PALL-07. COMPLEMENTARY CANNABIS THERAPY FOR MALIGNANT GLIOMA: INITIAL EXPERIENCE. Neuro-Oncology 2017, 19: vi169-vi169. PMCID: PMC5692009, DOI: 10.1093/neuonc/nox168.688.Peer-Reviewed Original ResearchMalignant glioma patientsCannabis treatmentGlioma patientsCannabis therapyInitial experienceTherapeutic useBeneficial palliative effectBrain tumor symptomsCertain medical conditionsLow usePalliative useStandard therapyTumor symptomsOral sprayTherapeutic roleMalignant gliomasPalliative effectMild fatigueAnaplastic astrocytomaMedical conditionsAstrocytoma casesGlioblastoma patientsPatientsSide effectsAnimal models
2016
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement
Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer 2016, 16: 842. PMID: 27809808, PMCID: PMC5096303, DOI: 10.1186/s12885-016-2890-0.Peer-Reviewed Original ResearchConceptsCase seriesAdvanced imagingTreatment planningCommon primary brain tumorNon-contrast enhancementPostcontrast MRI scansStandard care pathwayRecent clinical studiesPrimary brain tumorsContrast enhancementMagnetic resonance imaging (MRI) measurementsTumor Treating FieldsStandard treatment planningPrior therapyDisease activityNonmeasurable diseaseStandard therapySurvival benefitTumor burdenPoor prognosisTumor locationCare pathwayClinical evaluationClinical trialsPatient outcomes